Compare Grab Holdings Ltd. (GRAB) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Inovio Pharmaceuticals Inc — how do they compare? Grab Holdings Ltd. trades at $3.72 (market cap $15.62B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $96.26M). The key difference: Grab Holdings Ltd. is far larger — about 162.3× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| GRAB | INO | |
|---|---|---|
Market Cap | $15.62B | $96.26M |
Sector | Technology | Health |
52-Week High | $6.45 | $2.87 |
52-Week Low | $3.27 | $1.05 |
Enterprise Value | $11.32B | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.80, down 3.55% today but showing strong fundamental improvement with revenue growth from $2.8B in 2024 to $3.37B in 2025 and achieving profitability with $268M net income. Technical indicators show a bullish overall signal with neutral oscillators. Recent news highlights CEO share sales and Uber CEO's board departure, creating mixed sentiment despite analyst optimism.
The outlook remains positive with 91.67% analyst buy ratings and a $5.45 consensus target offering 43% upside. Key risks include competitive pressures in Southeast Asia's ride-hailing market and volatile cash flow patterns, but sustained revenue growth and margin expansion support long-term potential.
INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.
The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
